Celltrion Pharm Cash Per Share vs. Return On Equity
| 068760 Stock | KRW 61,800 600.00 0.96% |
For Celltrion Pharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Celltrion Pharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Celltrion Pharm utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Celltrion Pharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Celltrion Pharm over time as well as its relative position and ranking within its peers.
Celltrion |
Celltrion Pharm Return On Equity vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Celltrion Pharm's current stock value. Our valuation model uses many indicators to compare Celltrion Pharm value to that of its competitors to determine the firm's financial worth. Celltrion Pharm is number one stock in cash per share category among its peers. It also is number one stock in return on equity category among its peers . The ratio of Cash Per Share to Return On Equity for Celltrion Pharm is about 9,151 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Celltrion Pharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Celltrion Pharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Celltrion Return On Equity vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Celltrion Pharm |
| = | 815.33 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Celltrion Pharm |
| = | 0.0891 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Celltrion Return On Equity Comparison
Celltrion Pharm is currently under evaluation in return on equity category among its peers.
Celltrion Pharm Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Celltrion Pharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Celltrion Pharm will eventually generate negative long term returns. The profitability progress is the general direction of Celltrion Pharm's change in net profit over the period of time. It can combine multiple indicators of Celltrion Pharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea. Celltrionph is traded on Korean Securities Dealers Automated Quotations in South Korea.
Celltrion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Celltrion Pharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Celltrion Pharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Celltrion Pharm's important profitability drivers and their relationship over time.
Use Celltrion Pharm in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celltrion Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celltrion Pharm will appreciate offsetting losses from the drop in the long position's value.Celltrion Pharm Pair Trading
Celltrion Pharm Pair Trading Analysis
The ability to find closely correlated positions to Celltrion Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celltrion Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celltrion Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celltrion Pharm to buy it.
The correlation of Celltrion Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celltrion Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celltrion Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celltrion Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Celltrion Pharm position
In addition to having Celltrion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Dividend Beast Thematic Idea Now
Dividend Beast
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Celltrion Stock
To fully project Celltrion Pharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Celltrion Pharm at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Celltrion Pharm's income statement, its balance sheet, and the statement of cash flows.